Long-Term Survival and Risk of Liver Cancer After Direct-Acting Antiviral Treatment in HCV-Infected Patients Depending on the Degree of Liver Fibrosis
Cancers · 17.11.2026 · 18 (22) · 3665
DOI: 10.3390/cancers18223665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.11.2026. Verfasst von Krystyna Dobrowolska und 7 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Despite the high effectiveness of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection, patients remain at risk of liver malignancy and premature mortality. We evaluated long-term liver malignancy incidence and survival according to baseline fibrosis stage.
Methods
This retrospective, single-center study included 1399 DAA treatment records (2015–2025). After excluding 22 early deaths and 15 earlier treatment records from patients undergoing retreatment, 1362 patients were included in long-term analyses, beginning 12 weeks after DAA completion, irrespective of sustained virological response status. Of 24 patients with pre-existing HCC, 16 remained in the long-term cohort. Incident liver malignancies excluded recurrence or progression of pre-existing HCC. Time-to-event outcomes were assessed using Kaplan–Meier and Cox proportional hazards methods.
Results
During a median follow-up of 6.3 years, 33 liver malignancies occurred among 298 patients with cirrhosis (1343.6 person-years), compared with five cases among 1064 patients without cirrhosis (5705.5 person-years). Incidence rates were 2.46 and 0.09 cases per 100 person-years, respectively (incidence rate ratio [IRR] = 28; (95% CI: 10–92). Cirrhosis was strongly associated with liver malignancy development (hazard ratio [HR] = 19.1; 95% CI: 7.2–51.1). Five-year overall survival was 95.7% (95% CI: 94–97%) in patients with F0–F2 fibrosis, 86.4% (78.7–91.5%) in those with F3 fibrosis, and 65.7% (59.3–71.4%) in patients with cirrhosis (F4).
Conclusions
Liver malignancy risk persists following DAA treatment, particularly among patients with cirrhosis. Although the absolute incidence was low among patients without cirrhosis, cirrhosis was associated with substantially higher liver malignancy incidence and reduced long-term survival.
Zitieren
APA
Dobrowolska, K., Zarębska-Michaluk, D., Flisiak, R., Rzymski, P., Brzdęk, K., Janczura, J., Fedorek-Foltyn, K., & Brzdęk, M. (2026). Long-Term Survival and Risk of Liver Cancer After Direct-Acting Antiviral Treatment in HCV-Infected Patients Depending on the Degree of Liver Fibrosis. Cancers, 18(22), 3665. https://doi.org/10.3390/cancers18223665
Vancouver
Dobrowolska K, Zarębska-Michaluk D, Flisiak R, Rzymski P, Brzdęk K, Janczura J, et al. Long-Term Survival and Risk of Liver Cancer After Direct-Acting Antiviral Treatment in HCV-Infected Patients Depending on the Degree of Liver Fibrosis. Cancers. 2026;18(22):3665. doi:10.3390/cancers18223665
BibTeX
@article{Dobrowolska2026,
author = {Dobrowolska, Krystyna and Zarębska-Michaluk, Dorota and Flisiak, Robert and Rzymski, Piotr and Brzdęk, Kinga and Janczura, Jakub and Fedorek-Foltyn, Klaudia and Brzdęk, Michał},
title = {Long-Term Survival and Risk of Liver Cancer After Direct-Acting Antiviral Treatment in HCV-Infected Patients Depending on the Degree of Liver Fibrosis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3665},
doi = {10.3390/cancers18223665}
}
EUVIMED